Skip to main content

Table 1 Characteristics of the patients without and with persistent peritonitis at the time of ICU admission for initial septic surgery

From: Dynamic changes of microbial flora and therapeutic consequences in persistent peritonitis

  Without persistent peritonitis Persistent peritonitis P
n = 122 n = 98
Male gender, n (%) 59 (48) 58 (59) 0.10
Age, mean ± SD 62 ± 18 62 ± 14 0.99
Comorbidities    
  Cancer, n (%) 51 (42) 35 (36) 0.35
  Diabetes, n (%) 21 (17) 10 (10) 0.17
  Immunosuppression, n (%) 17 (14) 9 (9) 0.29
SAPS II score, mean ± SD 49 ± 23 50 ± 16 0.85
SOFA score, mean ± SD 6.8 ± 3.9 8.2 ± 3.2 0.01
Haemodynamic failure1, n (%) 49 (40) 59 (60) 0.003
Respiratory failure1, n (%) 32 (26) 36 (37) 0.09
Renal failure1, n (%) 16 (13) 22 (22) 0.07
Initial procedure leading to postoperative peritonitis    
  Emergency surgery, n (%) 43 (35) 47 (48) 0.056
  Elective surgery, n (%) 79 (65) 51 (52) -
Characteristics of the initial surgical procedure    
  Gastroduodenal surgery, n (%) 32 (26) 31 (32) 0.37
  Colonic surgery, n (%) 48 (39) 45 (46) 0.32
  Small bowel surgery, n (%) 20 (16) 19 (19) 0.59
  Other type of surgery, n (%) 22 (18) 11 (11) 0.18
Aetiology of postoperative peritonitis    
  Bowel perforation, n (%) 42 (34) 48 (49) 0.029
  Anastomotic leakage, n (%) 42 (34) 30 (30) 0.54
  Purulent collection, n (%) 17 (14) 20 (20) 0.21
  Other causes, n (%) 21 (18) 19 (19) 0.72
Primary site of infection above transverse mesocolon, n (%) 30 (25) 32 (33) 0.18
  Colonic site of infection, n (%) 40 (33) 35 (36) 0.65
  Small bowel site of infection, n (%) 49 (41) 32 (33) 0.25
  Gastric site of infection, n (%) 26 (21) 25 (26) 0.46
  Creation of ostomy, n (%) 62 (53) 54 (47) 0.52
Adequacy of empirical antibiotic therapy, n (%) 79 (65) 63 (64) 0.94
  Use of combination of antibiotic therapy, n (%) 88 (72) 84 (86) 0.02
  Use of carbapenems, n (%) 24 (20) 29 (30) 0.09
  Use of piperacillin/tazobactam, n (%) 84 (69) 62 (63) 0.38
  Use of vancomycin, n (%) 43 (35) 50 (51) 0.02
  Use of aminoglycosides, n (%) 50 (41) 53 (54) 0.053
  Use of empirical antifungal therapy, n (%) 30 (25) 43 (44) 0.002
  1. 1Grade 3 or 4 of the SOFA score. SAPS II, simplified acute physiology score II; SOFA, sequential organ failure assessment.